Nicoya Closes Acquisition of University of Toronto Startup LSK Technologies.

MANews-(C)2009-2022

Canada-based diagnostics and biotherapeutic digital proteomics solutions provider Nicoya Lifesciences has acquired LSK Technologies, a University of Toronto startup decentralizing laboratory testing with their high-throughput lab-in-a-box platform, the company said.

The acquisition comes amid the latest wave of SARS-CoV-2 infections, effectuating the need for versatile testing solutions to respond to rapidly evolving biological threats.

Together, the two firms are set to transform access and affordability of laboratory quality testing for a variety of applications, including point-of-need testing.

Nicoya has continued to build upon its novel method of viral detection since receiving over USD 2m in federal funding in 2021, incorporating their digital microfluidic and nanoplasmonic biosensor technology into a portable device for rapid antigen testing.

With the integration of LSK's amplification technology and associated IP, Nicoya will further broaden the applicability of their platform across a range of testing and diagnostic applications, while maintaining affordability and ease of use.

LSK was among the wave of companies that pivoted to fighting the global pandemic, working as a key supporting partner for a federal grant awarded in 2020 to scale up portable diagnostic testing.

Their core technology originated in a University of Toronto lab in 2016 for Zika virus detection, where co-founders Seray Ã[double dagger]iÃ[section sign]ek and Yuxiu (Livia) Guo invented and field tested the technology with Keith Pardee, Canada Research chair in Synthetic Biology in Human...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT